Mycophenolic acid counteracts B cell proliferation and plasmablast formation in patients with systemic lupus erythematosus
Open Access
- 1 January 2012
- journal article
- Published by Springer Science and Business Media LLC in Arthritis Research & Therapy
- Vol. 14 (3), R110
- https://doi.org/10.1186/ar3835
Abstract
Clinical trials revealed a high efficacy of mycophenolate mofetil (MMF) in inducing and maintaining remission in patients with class III-V-lupus nephritis. Also extrarenal manifestations respond to MMF treatment. However, few attempts have been undertaken to delineate its mechanism of action in systemic lupus erythematosus (SLE) a disease characterized by enhanced B cell activation. Clinical and paraclinical parameters of 107 patients with SLE were recorded consecutively and analyzed retrospectively. Patients were divided into treatment groups (MMF: n = 39, azathioprine (AZA) n = 30 and controls without immunosuppressive therapy n = 38). To further delineate the effect of mycophenolic acid (MPA) on naive and memory B cells in vitro assays were performed. Although patients taking AZA flared more frequently than patients on MMF or controls, the analysis of clinical parameters did not reveal significant differences. However, profound differences in paraclinical parameters were found. B cell frequencies and numbers were significantly higher in patients taking MMF compared to those on AZA but lower numbers and frequencies of plasmablasts were detected compared to AZA-treated patients or controls. Notably, MMF treatment was associated with a significantly higher frequency and number of transitional B cells as well as naive B cells compared to AZA treatment. Differences in T cell subsets were not significant. MPA abrogated in vitro proliferation of purified B cells completely but had only moderate impact on B cell survival. The thorough inhibition of B cell activation and plasma cell formation by MMF might explain the favorable outcomes of previous clinical trials in patients with SLE, since enhanced B cell proliferation is a hallmark of this disease.Keywords
This publication has 45 references indexed in Scilit:
- Influenza A/H1N1 vaccination of patients with SLE: can antimalarial drugs restore diminished response under immunosuppressive therapy?Rheumatology, 2012
- Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus NephritisNew England Journal of Medicine, 2011
- Mycophenolic Acid Differentially Impacts B Cell Function Depending on the Stage of DifferentiationPublished by The American Association of Immunologists ,2011
- Hypogammaglobulinemia and bronchiectasis in mycophenolate mofetil‐treated renal transplant recipients: an emerging clinical phenomenon?Clinical Transplantation, 2011
- Mycophenolic Acid-Mediated Suppression of Human CD4+ T Cells: More Than Mere Guanine Nucleotide DeprivationAmerican Journal of Transplantation, 2011
- Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis TrialAnnals Of The Rheumatic Diseases, 2010
- Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritisProceedings of the National Academy of Sciences, 2010
- Influenza virus vaccination in kidney transplant recipients: serum antibody response to different immunosuppressive drugsClinical Transplantation, 2010
- Efficacy of Mycophenolate Mofetil in Patients with Diffuse Proliferative Lupus NephritisNew England Journal of Medicine, 2000
- Mycophenolate Mofetil Impairs the Maturation and Function of Murine Dendritic CellsPublished by The American Association of Immunologists ,2000